Cerenome is trading 15.56% higher at $1.81 in pre-market, with the reason for the increase unconfirmed. - The shares closed at $1.57 on October 26. - No new company-specific announcement dated October 27 was found; the latest listed release, on October 21, covered preclinical REYOBIQ findings. - Available market context does not establish a broad-market cause, and no pre-market volume or activity details were provided.